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for Depression were found in all of 51 investigated patients (100%), but with
inverse correlation. As less was cognitive impairment and memory deficit as
higher were scores in depression Scales, and as more profound was dementia,
patients were less depressed. 33 patients were “naive”, 18 patients had previ-
ous uneffective treatment with so-called neuroprotectors and vitamins. 6 pa-
tients were treated with MAO inhibitor (amitriptyline) but discontinue their
treatment because of memory detoriation and worsening of the activities of
daily living. 16 patients with MCI successfully overcome their depressive ep-
isode when started effective treatment for their memory impairment.Conclu-
sions: Both depression and dementia are existing co-morbidities especially in
elderly, and need in-time and precise evaluation. Early and correct diagnosis of
both conditions must serve as basis for further effective management. In MCI
effective treatment ofmemory impairment could be paramount for general im-
provement of the mood and reducing of the stress, treatment of patients with
Dementia with MAO is usually complicated because of drowsiness and addi-
tional reduction of daily activities. Every patients with dementia must be eval-
uated for depression and treat accordingly the neurological and cognitive
deficit.
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Background: Frontotemporal dementia (FTD) is a complex presenile disorder
characterized by behavioural changes and executive functions, expression of
fronto-temporal degeneration. Hereditary FTD accounts for 20-30% of cases
and, in the past decade, mutations in the microtubule associated protein tau
(MAPT)gene were identified as a main genetic causes of familial FTD. In
2006,mutations in the gene encoding progranulin (PGRN) were reported, to ac-
count for a wide part of the familial FTD cases. Clinically, an high phenotypic
variability within and among the kindreds is reported in the familial FTD asso-
ciated with PGRNmutations and occasionally the memory deficits are the first
symptoms, resembling Alzheimer’s disease (AD). We report an Italian family
with dementia associated with a PGRN mutation characterized by a deletion
of 4 base pairs inside the intron 6 of the gene, leading to haploin sufficiency
In our kindred, all three affected patients carried the mutation, but presented
very different clinical phenotypes, evoking FTD, AD and rapidly-progressive
dementia mimicking prion disease. Methods: Informations on the members
of the first, second and third generations were obtained conducting interviews
with relatives, while for the three patients studied, the clinical evidence of de-
mentia symptoms and their characterization was documented directly with se-
quential neurological examinations, cognitive assessments and neuroimaging.
Blood sample collection and DNA extraction from peripheral blood lympho-
cytes for genetic analysis were performed after written informed consent of
the patients.Results: In our pedigree, the PGRN mutated patients are affected
by dementia with three different clinical pictures: FTD, AD and rapidly pro-
gressive dementia mimicking prion disease. Neuropsychological examinations
supported these diagnoses, documenting generalized deficits of cortical func-
tions in AD patient and deficits in executive functions and in language in
FTD patient. Regarding neuroimaging, in the same two cases MRI results do
not correspond to the clinical diagnosis. Conclusions: These findings con-
firms the marked heterogeneity of the clinico-radiological features in pa-
tients with PGNR mutations and underline the need of considering
mutations of this gene as causes of familial dementing diseases with
atypical or uncommon features or discrepancies between the clinical
and the neuroimaging findings.
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Background: Magnetic resonance imaging (MRI), cerebral blood flow single
photon emission computed tomography (CBF-SPECT), fluorodeoxyglucose-
positron emission tomography (FDG-PET), and cerebrospinal fluid (CSF) bio-
markers are used for the diagnosis of Alzheimer’s disease (AD). The purpose of
our studywas to reveal the relativeusefulnessof thesediagnostic tools in clinical
practice in amemory clinic.Methods: In 207 patients with probable AD in our
memory clinic, medial temporal lobe atrophy onMRI, hypoperfusion/hypome-
tabolism of the parieto-temporal lobe and posterior cingulate gyrus in ethylcys-
teinate dimmer-CBF-SPECT/FDG-PET, and abnormalities of CSF amyloid
beta-protein 1-42, total tau, and phosphorylated tau were evaluated as findings
characteristic of AD.Results: The findings characteristic of AD were found in
77.4% of all AD patients with MRI, 81.6% with CBF-SPECT, 93.1% with
FDG-PET, and 90.0%with CSF biomarkers. At the stage of Clinical Dementia
Rating (CDR) 0.5, CSF biomarkers were the most sensitive (90.0%); at the
stage of CDR 1, FDG-PET (96.7%) and CSF biomarkers (95.5%) were highly
sensitive. At the stage of CDR 2, all tools showed high positive percentages.
Conclusions: The diagnosis of AD was most often supported by CSF bio-
markers and FDG-PETat the early stage of dementia (CDR 1) and by CSF bio-
markers at the earlier stage (CDR 0.5).
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Background: Nonfluent primary progressive aphasias are generally di-
vided into primary nonfluent aphasia (PNFA) and logopenic progressive
aphasia (LPA), with distinct underlying pathology: PNFA belongs to the
frontotemporal dementia spectrum whereas LPA is predominantly associ-
ated with Alzheimer pathology. Clinically, PNFA and LPA present with
similar expressive language deficits and are difficult to differentiate in
life. Facial emotion recognition is typically impaired in patients with Alz-
heimer’s disease (AD). Whether performance on facial emotion recogni-
tion tasks differs in PNFA and LPA patients and whether LPA patients
experience deficits that are similar to those observed in AD is unknown.
Methods: Fourteen PNFA, 12 LPA and 18 AD patients were recruited along
with 38 age- and education-matched healthy controls. Participants were ad-
ministered four tasks measuring different aspects of emotion recognition:
face perception, identity matching, emotion matching and emotion selec-
tion, as well as the Ekman 60 face recognition task. Results: Compared
to the healthy controls, all three patient groups were significantly impaired
on the Ekman 60 face recognition task. In contrast, patient groups exhibited
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